Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Do we need routine integrase resistance testing before starting antiretroviral therapy?
Journal: The lancet. HIV
Published: January 10, 2025
Academic Medical Centers and the U.S. Department of Veterans Affairs: A 75-Year Partnership Influences Medical Education, Scientific Discovery, and Clinical Care.
Journal: Academic medicine : journal of the Association of American Medical Colleges
Published: May 04, 2022
Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
Journal: Antimicrobial agents and chemotherapy
Published: May 03, 2022
Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
Journal: Current opinion in HIV and AIDS
Published: December 06, 2021
Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals.
Journal: AIDS (London, England)
Published: September 29, 2021
Fostemsavir for the treatment of HIV.
Journal: Expert review of anti-infective therapy
Published: December 17, 2020
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Journal: HIV medicine
Published: June 19, 2020
SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?
Journal: PloS one
Published: May 14, 2020
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Journal: The lancet. HIV
Published: April 30, 2020
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Journal: The New England journal of medicine
Published: March 27, 2020
Last Updated: 09/26/2026